keyword
MENU ▼
Read by QxMD icon Read
search

Tiotropium

keyword
https://www.readbyqxmd.com/read/29446377/therapeutic-effects-of-a-long-acting-cholinergic-receptor-blocker-tiotropium-bromide-on-asthma
#1
Li Zhang, Guangyin Huang, Long Jin, Shuhua Han
BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma. MATERIAL AND METHODS A total of 160 patients with moderate persistent asthma were randomly divided into 4 groups (n=40): the 3 control groups were given fluticasone propionate aerosol (group A), salmeterol-fluticasone propionate inhalant (group B), and tiotropium bromide inhalation powder combined with salmeterol-fluticasone propionate inhalant (group C), respectively, and the experimental group received tiotropium bromide inhalation powder combined with fluticasone propionate aerosol (group D) and salbutamol was used to relieve symptoms when necessary...
February 15, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29439648/effect-of-12-weeks-of-once-daily-tiotropium-olodaterol-on-exercise-endurance-during-constant-work-rate-cycling-and-endurance-shuttle-walking-in-chronic-obstructive-pulmonary-disease
#2
François Maltais, Denis O'Donnell, Juan Bautista Gáldiz Iturri, Anne-Marie Kirsten, Dave Singh, Alan Hamilton, Kay Tetzlaff, Yihua Zhao, Richard Casaburi
BACKGROUND: The TORRACTO ® study evaluated the effects of tiotropium/olodaterol versus placebo on endurance time during constant work-rate cycling and constant speed shuttle walking in patients with chronic obstructive pulmonary disease (COPD) after 12 weeks of treatment. METHODS: The effects of once-daily tiotropium/olodaterol (2.5/5 and 5/5 μg) on endurance time during constant work-rate cycle ergometry (CWRCE) after 6 and 12 weeks of treatment were compared with placebo in patients with COPD in a randomized, double-blind, placebo-controlled, parallel-group clinical trial...
January 2018: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/29438808/effect-of-tiotropium-on-spontaneous-expiratory-flow-volume-curves-during-exercise-in-gold-1-2-copd
#3
Janos Porszasz, Nicolò Carraro, Robert Cao, Ashwani Gore, Shuyi Ma, Thomas Jiang, François Maltais, Gary T Ferguson, Denis E O'Donnell, Asif Shaikh, Harry B Rossiter, Richard Casaburi
This substudy of a large, randomized, controlled trial (NCT01072396) examined tiotropium (18 μg qd) effects on dynamic hyperinflation during constant work rate treadmill exercise. Areas-under-the-spontaneous expiratory flow-volume (SEFV)-curves were compared in 20 COPD patients and 16 age-matched untreated controls, using rectangular area ratio (RAR) between peak intrabreath and end-expiratory flow. Seven patients exhibited SEFV curve concavity with RAR ≤ 0.5 (RAR low ) in ≥1 test without tiotropium; (mean ± SD FEV 1 : 1...
February 10, 2018: Respiratory Physiology & Neurobiology
https://www.readbyqxmd.com/read/29427984/controlling-the-risk-domain-in-pediatric-asthma-through-personalized-care
#4
William C Anderson, Stanley J Szefler
Strategies to control the risk domain of NHLBI EPR-3 (National Heart, Lung, and Blood Institute Expert Panel Report-3) asthma guidelines, which includes exacerbations requiring systemic corticosteroids, reduction in lung growth, and progressive loss of lung function, and treatment-related adverse effects, are evolving in children and adolescents. Increasing evidence demonstrates that children and adolescents with asthma are at risk of a reduction in lung growth, leading to lower lung function and potentially chronic obstructive pulmonary disease as adults...
February 2018: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29422778/cost-effectiveness-of-tiotropium-versus-omalizumab-for-uncontrolled-allergic-asthma-in-us
#5
Zafar Zafari, Mohsen Sadatsafavi, J Mark FitzGerald
Background: A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies (namely omalizumab) and more recently tiotropium bromide have been recommended for this subgroup of patients. The purpose of this study was to assess the cost-effectiveness of tiotropium versus omalizumab as add-on therapies to ICS + LABA for patients with uncontrolled allergic asthma...
2018: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/29420077/tiotropium-added-to-low-to-medium-dose-inhaled-corticosteroids-ics-versus-low-to-medium-dose-ics-alone-for-adults-with-mild-to-moderate-uncontrolled-persistent-asthma-a-systematic-review-and-meta-analysis
#6
Liqun Wang, Ruirui Zhou, Xiaohui Xie
OBJECTIVE: To assess the efficacy and safety profile of tiotropium when added to low- to medium-dose inhaled corticosteroid (ICS) regimen versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma. DATA SOURCES: The online databases Pubmed, Embase and the Cochrane Library were searched for relevant data published up to November 14, 2017; we also conducted a supplementary search using clinicaltrials.gov. STUDY SELECTIONS: Only randomized control trials were included in this review...
February 8, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29408386/tiotropium-attenuates-refractory-cough-and-capsaicin-cough-reflex-sensitivity-in-patients-with-asthma
#7
Kensuke Fukumitsu, Yoshihiro Kanemitsu, Takamitsu Asano, Norihisa Takeda, Hiroya Ichikawa, Jennifer Maries Go Yap, Satohi Fukuda, Takehiro Uemura, Osamu Takakuwa, Hirotsugu Ohkubo, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Atsushi Nakamura, Masaya Takemura, Akio Niimi
BACKGROUND: Asthmatic cough is often refractory to standard treatments such as inhaled corticosteroids and long-acting β2 agonists (ICS/LABA). Tiotropium may modulate cough reflex sensitivity of acute viral cough, but its efficacy in asthmatic cough remains unknown. OBJECTIVE: To evaluate whether tiotropium improves cough and cough reflex sensitivity in asthmatic patients refractory to ICS/LABA. METHODS: Seventeen consecutive asthmatic patients with chronic cough despite the use of ICS/LABA [13 females; 43...
February 2, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29368127/efficacy-and-safety-of-tiotropium-in-children-and-adolescents
#8
REVIEW
Eckard Hamelmann, Stanley J Szefler
Asthma is one of the most common chronic diseases in children, with a high proportion of patients demonstrating poor control despite the availability of disease management guidelines. Global Initiative for Asthma guidelines include tiotropium as an add-on therapy option at Steps 4 and 5 in patients aged ≥ 12 years with a history of exacerbations, and tiotropium delivered via the Respimat® Soft Mist™ Inhaler has recently been approved for use as once-daily maintenance therapy for children with asthma over the age of 6 years in the USA...
January 24, 2018: Drugs
https://www.readbyqxmd.com/read/29361463/tiotropium-from-copd-to-young-children-with-asthma
#9
Alvaro A Cruz
No abstract text is available yet for this article.
January 17, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29361462/safety-and-efficacy-of-tiotropium-in-children-aged-1-5-years-with-persistent-asthmatic-symptoms-a-randomised-double-blind-placebo-controlled-trial
#10
Elianne J L E Vrijlandt, Georges El Azzi, Mark Vandewalker, Ned Rupp, Thomas Harper, LeRoy Graham, Stanley J Szefler, Petra Moroni-Zentgraf, Ashish Sharma, Sebastian D Vulcu, Ralf Sigmund, Bo Chawes, Michael Engel, Hans Bisgaard
BACKGROUND: Few studies have assessed the safety and efficacy of potential asthma medications in children younger than 5 years. We descriptively assessed the safety and efficacy of tiotropium, a long-acting anticholinergic drug, in children aged 1-5 years with persistent asthmatic symptoms. METHODS: This exploratory 12-week, randomised, double-blind, placebo-controlled, parallel-group, phase 2/3, regulatory multicentre trial was done at 32 hospitals, clinics, and clinical research units in 11 countries in Asia, Europe, and North America...
January 17, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29355547/%C3%AE-blockers-in-chronic-obstructive-pulmonary-disease-a-cohort-study-from-the-tonado%C3%A2-research-programme
#11
François Maltais, Roland Buhl, Andrea Koch, Valeria C Amatto, Jim Reid, Lars Grönke, Ulrich Bothner, Florian Voß, Lorcan McGarvey, Gary T Ferguson
BACKGROUND: Cardiovascular disease is a frequent co-morbidity in patients with chronic obstructive pulmonary disease (COPD). Many clinicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiveness in preventing cardiovascular events. METHODS: The large (5,162 patients) phase III TONADO® 1 and 2 studies assessed lung function and patient-reported outcomes (PROs) in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment over 1 year...
January 16, 2018: Chest
https://www.readbyqxmd.com/read/29354671/recruiting-patients-after-hospital-discharge-for-acute-exacerbation-of-copd-challenges-and-lessons-learned
#12
Gary T Ferguson, Bonnie Beck, Emmanuelle Clerisme-Beaty, Dacheng Liu, Byron M Thomashow, Robert A Wise, Richard ZuWallack, Barry J Make
Background: Hospitalizations for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with increased mortality and decreased quality of life. Replicate hospital discharge studies were initiated to examine efficacy and safety of once-daily tiotropium HandiHaler® versus placebo, in addition to usual care, in patients discharged from the hospital after an AECOPD. Methods: Both studies were randomized, placebo-controlled, double-blind, parallel-group, multicenter, with inclusion/exclusion criteria providing a diverse COPD patient cohort hospitalized for ≤14 days with AECOPD...
August 10, 2017: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://www.readbyqxmd.com/read/29343950/examining-30-day-copd-readmissions-through-the-emergency-department
#13
Michael E Rezaee, Charlotte E Ward, Bonita Nuanez, Daniel A Rezaee, Jeffrey Ditkoff, Alexandra Halalau
Background: Thirty-day readmission in COPD is common and costly, but potentially preventable. The emergency department (ED) may be a setting for COPD readmission reduction efforts. Objective: To better understand COPD readmission through the ED, ascertain factors associated with 30-day readmission through the ED, and identify subgroups of patients with COPD for readmission reduction interventions. Patients and methods: A retrospective cohort study was conducted from January 2009 to September 2015 in patients with COPD of age ≥18 years...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29337266/comparison-of-the-in-vitro-pharmacological-profiles-of-long-acting-muscarinic-antagonists-in-human-bronchus
#14
Emmanuel Naline, Stanislas Grassin Delyle, Hélène Salvator, Marion Brollo, Christophe Faisy, Tatiana Victoni, Charlotte Abrial, Philippe Devillier
BACKGROUND AND PURPOSE: Long-acting muscarinic antagonists (LAMAs) have been recommended for the treatment of chronic obstructive pulmonary disease and (more recently) asthma. However, the in vitro pharmacological profiles of the four LAMAs currently marketed (tiotropium, umeclidinium, aclidinium and glycopyrronium) have not yet been compared (relative to ipratropium) by using the same experimental approach. EXPERIMENTAL APPROACH: With a total of 560 human bronchial rings, we investigated the antagonists' potency, onset and duration of action for inhibition of the contractile response evoked by electrical field stimulation...
January 11, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29332320/the-role-of-tiotropium-olodaterol-dual-bronchodilator-therapy-in-the-management-of-chronic-obstructive-pulmonary-disease
#15
REVIEW
David M G Halpin
Bronchodilator therapy is central to the management of chronic obstructive pulmonary disease and are recommended as the preferred treatment by the Global Obstructive Lung Disease Initiative (GOLD). Long acting anti-muscarinics (LAMA) and long acting β₂ agonists (LABA) are both more effective than regular short-acting drugs but many patients remain symptomatic despite monotherapy with these drugs. Combination therapy with LAMA and LABA increases the therapeutic benefit while minimizing dose-dependent side effects of long-acting bronchodilator therapy...
January 2018: Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29328595/tiotropium-in-early-stage-copd
#16
Pixin Ran, Yumin Zhou, Wei-Jie Guan
No abstract text is available yet for this article.
December 7, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328594/tiotropium-in-early-stage-copd
#17
Scott R Garrison, G Michael Allan
No abstract text is available yet for this article.
December 7, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328593/tiotropium-in-early-stage-copd
#18
Edward Kerwin
No abstract text is available yet for this article.
December 7, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328592/tiotropium-in-early-stage-copd
#19
Guoqing Qian, Fengying Ying, Guoxiang Li
No abstract text is available yet for this article.
December 7, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29322375/predictors-of-short-term-lama-ineffectiveness-in-treatment-na%C3%A3-ve-patients-with-moderate-to-severe-copd
#20
Vladimir Fijačko, Marina Labor, Mirjana Fijačko, Sanda Škrinjarić-Cincar, Slavica Labor, Iva Dumbović Dubravčić, Tatjana Bačun, Aleksandar Včev, Sanja Popović-Grle, Davor Plavec
BACKGROUND: No specific (only subgroup) recommendations for the use of long-acting muscarinic antagonists in chronic obstructive pulmonary disease (COPD) exist. The aim of this exploratory hypothesis generating study was to assess whether different phenotypic/endotypic characteristics could be determinants of the short-term ineffectiveness of the initial tiotropium bromide monotherapy in treatment naïve moderate to severe COPD patients. METHODS: A total of 51 consecutively recruited COPD patients were followed for 3 months after the initial evaluation and prescribed initial treatment (tiotropium)...
January 10, 2018: Wiener Klinische Wochenschrift
keyword
keyword
8894
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"